Galectin Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GALT Nasdaq 2836 galectintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galectin Therapeutics Inc.

Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks - Dec 9th, 2024 2:35 pm
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Nov 18th, 2024 1:00 pm
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - Nov 14th, 2024 1:00 pm
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Oct 15th, 2024 12:00 pm
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - Sep 30th, 2024 12:00 pm
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 12:30 pm
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update - Aug 13th, 2024 12:00 pm
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer - Aug 1st, 2024 12:00 pm
Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20% - Jul 30th, 2024 12:39 pm
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress - Jun 4th, 2024 12:00 pm
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update - May 15th, 2024 12:00 pm
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference - May 13th, 2024 12:00 pm
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis - Apr 9th, 2024 12:00 pm
Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments - Mar 29th, 2024 1:11 pm
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update - Mar 29th, 2024 12:00 pm
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development - Mar 12th, 2024 12:00 pm
Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21% - Feb 21st, 2024 11:53 am